ReviewBlood reviews2017
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.
Review in Blood reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Article
- 68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.Clinical nuclear medicine · 2026Article
- In-situ polymerization-mediated glycan density measurement on extracellular vesicle surface for acute myeloid leukemia diagnosis.Journal of nanobiotechnology · 2026Article
- Central Nervous System Involvement in Acute Myeloid Leukemia: From Pathophysiology to Neuroradiologic Features and the Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
- PheCode-guided multi-modal topic modeling of electronic health records improves disease incidence prediction and GWAS discovery from UK Biobank.Briefings in bioinformatics · 2026Article
- New molecular targets in acute leukemias: cytoskeletal regulatory proteins.Biochemical Society transactions · 2025Review
- Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives.Hematology reports · 2025Review
- Article
- Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.Theranostics · 2025Review
- Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.Advances in experimental medicine and biology · 2025Review
- Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast].Blood and lymphatic cancer : targets and therapy · 2025Article
- Article
- Acute myeloid leukemia: An unusual manifestation of the trachea.Laryngoscope investigative otolaryngology · 2024Article
- Integrated analysis and validation reveal CYTH4 as a potential prognostic biomarker in acute myeloid leukemia.Oncology letters · 2024Article
- Prevalence, Risk Factors, and Prognostic Value of Anxiety and Depression in Acute Myeloid Leukemia.Acta haematologica · 2024Article
- AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.Theranostics · 2024Article
- Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.Frontiers in oncology · 2024Review
- Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.Frontiers in immunology · 2024Article
- Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects.Cancers · 2023Review
- Label-Free CD34+ Cell Identification Using Deep Learning and Lens-Free Shadow Imaging Technology.Biosensors · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients. For patients with circulating blasts, it is reasonable to perform the necessary studies needed for diagnosis and risk stratification, including multiparametric flow cytometry, cytogenetics, and molecular analysis, on a peripheral blood specimen. The day 14 marrow is used to document hypocellularity in response to induction chemotherapy, but it is unclear if that assessment is necessary as it often does not affect immediate management. Currently, response assessments performed at count recovery for evaluation of remission and measurable residual disease rely on bone marrow sampling. For monitoring of relapse, peripheral blood evaluation may be adequate, but the sensitivity of bone marrow testing is in some cases superior. While bone marrow evaluation can certainly be avoided in particular situations, this cumbersome and uncomfortable procedure currently remains the de facto standard for response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.